Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS | P14324 | 10/20 | 0.42 |
| ▸ | GGPS1 | O95749 | 7/20 | 0.42 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.34 |
| ▸ | PLA2G2C | Q5R387 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7549129 | 0.98 | FDPS (0.44) | FDPSGGPS1SMPD1PLA2G2CTP53 | |
| Choline SCHEMBL28126923 | 0.87 | PSMD14 (0.38) | FDPSGGPS1 | |
| SCHEMBL4566609 | 0.81 | FDPS (0.43) | FDPSGGPS1SMPD1 | |
| SCHEMBL2039696 | 0.75 | FDPS (0.39) | FDPSGGPS1TP53CYP1A2CYP2D6 | |
| SCHEMBL302211 | 0.75 | FDPS (0.39) | FDPSGGPS1TP53CYP1A2CYP2D6 | |
| SCHEMBL4552174 | 0.74 | FAAH (0.42) | TP53CYP1A2MAPTCYP2C9CYP2C19 | |
| SCHEMBL4552697 | 0.74 | FAAH (0.42) | TP53CYP1A2MAPTCYP2C9CYP2C19 | |
| SCHEMBL7530555 | 0.74 | LMNA (0.41) | FDPSGGPS1TP53CYP1A2CYP2D6 | |
| SCHEMBL25815 | 0.74 | LMNA (0.41) | FDPSGGPS1TP53CYP1A2CYP2D6 | |
| SCHEMBL2226505 | 0.74 | LMNA (0.41) | FDPSGGPS1TP53CYP1A2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 268 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2964336-B2 | COLOUR CHANGING COMPOSITION IN EMULSION FORM COMPRISING A PARTIALLY NEUTRALIZED, CROSSLINKED ACRYLIC HOMOPOLYMER OR COPOLYMER | OREAL (FR) | 2024-06-26 | — | — | EP | claimed |
| US-11129776-B2 | Compositions for cosmetic raw material and methods for making the same | KPT LTD. (KR) | 2021-09-28 | — | — | US | claimed |
| WO-2020232701-A1 | MONOSACCHARIDE LABELED NANOLIPOSOME DRUG DELIVERY SYSTEM, PREPARATION METHOD THEREFOR AND USE OF SAME AS TARGETING DELIVERY VECTOR FOR DRUG | 法玛科技顾问股份有限公司 (CN) | 2020-11-26 | — | — | WO | claimed |
| EP-3137045-B1 | COMPOSITION COMPRISING MICROCAPSULES CONTAINING PARTICLES WITH A HIGH WET POINT | OREAL (FR) | 2020-02-19 | — | — | EP | claimed |
| EP-3137048-B1 | COMPOSITION COMPRISING MICROCAPSULES CONTAINING REFLECTIVE PARTICLES | OREAL (FR) | 2020-02-12 | — | — | EP | claimed |
| EP-2823804-B1 | Color changing composition comprising pigments and a high amount of water | OREAL (FR) | 2019-08-21 | — | — | EP | claimed |
| EP-2823803-B1 | Color changing composition in O/W emulsion in the form of oleosomes | OREAL (FR) | 2019-08-21 | — | — | EP | claimed |
| EP-2823805-B1 | Color changing composition in O/W emulsion form comprising a gemini surfactant | OREAL (FR) | 2019-08-21 | — | — | EP | claimed |
| EP-2964186-B1 | COLOUR CHANGING COMPOSITION IN EMULSION FORM COMPRISING AN EMULSIFYING HYDROPHILIC GELIFYING AGENT | OREAL (FR) | 2018-11-28 | — | — | EP | claimed |
| EP-2964336-B1 | COLOUR CHANGING COMPOSITION IN EMULSION FORM COMPRISING A PARTIALLY NEUTRALIZED, CROSSLINKED ACRYLIC HOMOPOLYMER OR COPOLYMER | OREAL (FR) | 2018-08-08 | — | — | EP | claimed |
| WO-2013107002-A1 | COLOUR CHANGING COMPOSITION WITH POLYOLS | L'OREAL (FR) | 2013-07-25 | — | — | WO | claimed |
| US-8318508-B2 | Patterning with compositions comprising lipid | NORTHWESTERN UNIVERSITY (US) | 2012-11-27 | — | — | US | claimed |
| US-8192794-B2 | Massively parallel lithography with two-dimensional pen arrays | NORTHWESTERN UNIVERSITY (US) | 2012-06-05 | — | — | US | claimed |
| EP-2173475-A2 | PATTERNING WITH COMPOSITIONS COMPRISING LIPID | Northwestern University (US) | 2010-04-14 | — | — | EP | claimed |
| US-20090325816-A1 | Massively parallel lithography with two-dimensional pen arrays | NORTHWESTERN UNIVERSITY | 2009-12-31 | — | — | US | claimed |
| US-20090143246-A1 | Patterning with compositions comprising lipid | NORTHWESTERN UNIVERSITY | 2009-06-04 | — | — | US | claimed |
| WO-2008156732-A2 | PATTERNING WITH COMPOSITIONS COMPRISING LIPID | NORTHWESTERN UNIVERSITY (US) | 2008-12-24 | — | — | WO | claimed |
| EP-1750776-A2 | OLIGONUCLEOTIDES COMPRISING A C5-MODIFIED PYRIMIDINE | Alnylam Pharmaceuticals Inc. (US) | 2007-02-14 | — | — | EP | claimed |
| WO-2006073458-A2 | OLIGONUCLEOTIDES COMPRISING A C5-MODIFIED PYRIMIDINE | ALNYLAM PHARMACEUTICALS, INC. (US) | 2006-07-13 | — | — | WO | claimed |
| US-20050288244-A1 | Oligonucleotides comprising a C5-modified pyrimidine | ALNYLAM PHARMACEUTICALS, INC. (US) | 2005-12-29 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050288244-A1 | Oligonucleotides comprising a C5-modified pyrimidine | DUT, TYMP, DPYD | FDPS 330/4885GGPS1 222/4885SMPD1 507/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.